Facebook
X
LinkedIn
Forward
Innovative Approaches to ATTR-CM: Addressing Health Disparities in African American Populations
Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive and underdiagnosed condition characterized by the deposition of misfolded transthyretin protein in the heart, leading to restrictive cardiomyopathy and heart failure. ATTR-CM disproportionately affects African Americans due to the high prevalence of the Val122Ile mutation, which significantly increases their risk.
Led by chair Dr. Keith C. Ferdinand, alongside experts Dr. Ola O. Akinboboye and Dr. Frederick L. Ruberg, this symposium at the 20th Annual CMHC meeting highlights the critical importance of early detection through imaging, biomarkers, and genetic testing, particularly in African Americans. The experts also review the significant advancements in treatment options, including novel targeted therapies that offer hope for improved disease management. To emphasize the importance of best clinical practices, a patient advocate shares their experience, shedding light on the challenges faced by those living with ATTR-CM.
Target Audience
The educational design of this activity addresses the needs of U.S. based healthcare professionals, including internists, family practice physicians, cardiologists, lipidologists, and advanced practice providers.
Learning Objectives
After completing this activity, the participant should be better able to:
- Define the pathophysiology, prevalence, and types of transthyretin cardiac amyloidosis (ATTR-CM)
- Recognize the disproportionate burden of ATTR-CM in African Americans and the significance of Val122l mutation
- List screening and diagnostic methods to optimize the early identification of patients with ATTR-CM, including the African American population, based on guidelines.
- Review the different options for the treatment of ATTR-CM, including new and emerging novel targeted agents.
- Select the best treatment for ATTR-CM patients, particularly African Americans, to optimize clinical outcomes.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, FPCNA (hon.)
Gerald S. Berenson Endowed Chair in Preventative Cardiology
Professor of Medicine
Tulane University School of Medicine
New Orleans, LA
Ola O. Akinboboye, MD, MPH, MBA
Medical Director
Laurelton Heart Specialist PC
Donald and Barbara Zucker School of Medicine at Hofstra-Northwell
Rosedale, NY
Frederick L. Ruberg, MD
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, MA
ESTIMATED TIME TO COMPLETE ACTIVITY
1.25 hour
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Alnylam Pharmaceuticals, BridgeBio Pharma, Inc, and held in partnership with the Association of Black Cardiologists, Inc. (ABC).
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
Partners designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
Partners designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-094-H01-P Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 1.25 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from February 27, 2026 through February 27, 2027.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Ferdinand, faculty for this educational activity, discloses the following:
- Consultant, Advisor, Speaker: Amgen, Novartis, Boehringer Ingelheim, Medtronic, AstraZeneca
Dr. Akinboboye, faculty for this educational activity, discloses the following:
Consultant, Advisor, Speaker: Alnylam Pharmaceuticals, Astra Zeneca, Bridgebio, Pfizer Inc.
Dr. Ruberg, faculty for this educational activity, discloses the following:
Researcher: BridgeBio Pharm, TriNetX/AstraZeneca, Anumana, Pfizer
Consultant, Advisor, Speaker: eMyosound, Attralus
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 CDE
- 1.25 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.